NPM1 and acute myeloid leukemia: In a further phase 3 trial for NPM1 mutated de novo AML (n = 588) randomized to IC (idarubicin, cytarabine, etoposide and ATRA) plus/minus GO 3 mg/m2 on day 1 there was no difference in cCR rate after induction therapy (88.5% versus 85.3%, p = 0.28) but the GO treatment was associated with a higher ED rate (7.5% vs. 3.4%; p = 0.02), particularly in patients aged over 70 years.